Hims & Hers Health, Inc. (NYSE:HIMS) Insider Soleil Boughton Sells 3,236 Shares

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 3,236 shares of Hims & Hers Health stock in a transaction on Monday, March 31st. The shares were sold at an average price of $27.77, for a total transaction of $89,863.72. Following the completion of the sale, the insider now owns 170,285 shares in the company, valued at approximately $4,728,814.45. This trade represents a 1.86 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, February 18th, Soleil Boughton sold 4,152 shares of Hims & Hers Health stock. The stock was sold at an average price of $60.69, for a total value of $251,984.88.
• On Monday, February 3rd, Soleil Boughton sold 4,153 shares of Hims & Hers Health stock. The shares were sold at an average price of $35.30, for a total transaction of $146,600.90.
• On Tuesday, January 21st, Soleil Boughton sold 54,153 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.90, for a total transaction of $1,619,174.70.
• On Monday, January 6th, Soleil Boughton sold 268,932 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.75, for a total transaction of $7,462,863.00.

Hims & Hers Health Stock Down 7.4 %

Hims & Hers Health stock traded down $2.06 during mid-day trading on Friday, reaching $25.93. 27,621,633 shares of the company's stock traded hands, compared to its average volume of 14,730,901. Hims & Hers Health, Inc. has a 12-month low of $11.20 and a 12-month high of $72.98. The stock has a 50 day moving average of $39.82 and a two-hundred day moving average of $29.94. The company has a market cap of $5.76 billion, a price-to-earnings ratio of 58.93 and a beta of 1.65.

Remove Ads

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. As a group, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds have recently added to or reduced their stakes in HIMS. SlateStone Wealth LLC grew its stake in shares of Hims & Hers Health by 4.0% during the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company's stock valued at $257,000 after buying an additional 413 shares during the last quarter. Blume Capital Management Inc. grew its holdings in shares of Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 600 shares during the last quarter. Summit Investment Advisors Inc. lifted its holdings in Hims & Hers Health by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company's stock valued at $480,000 after buying an additional 628 shares in the last quarter. Cim LLC boosted its position in Hims & Hers Health by 1.0% in the 4th quarter. Cim LLC now owns 71,869 shares of the company's stock valued at $1,738,000 after buying an additional 694 shares during the period. Finally, Harbour Investments Inc. increased its position in shares of Hims & Hers Health by 18.8% during the fourth quarter. Harbour Investments Inc. now owns 5,269 shares of the company's stock worth $127,000 after acquiring an additional 833 shares during the period. 63.52% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

HIMS has been the topic of several analyst reports. Truist Financial lifted their price target on shares of Hims & Hers Health from $24.00 to $39.00 and gave the stock a "hold" rating in a research note on Wednesday, February 26th. Bank of America boosted their price target on Hims & Hers Health from $21.00 to $22.00 and gave the company an "underperform" rating in a report on Tuesday, March 18th. Morgan Stanley cut Hims & Hers Health from an "overweight" rating to an "equal weight" rating and upped their price target for the stock from $42.00 to $60.00 in a research report on Tuesday, February 18th. Needham & Company LLC boosted their price objective on Hims & Hers Health from $31.00 to $61.00 and gave the company a "buy" rating in a research note on Tuesday, February 25th. Finally, BTIG Research assumed coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They set a "buy" rating and a $35.00 target price on the stock. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of "Hold" and a consensus price target of $37.31.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.